SCHEMBL6279147

SCHEMBL6279147

O=C(O)N1CCc2c(CNC3CC3)cccc2C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.44
▸ MAPT P10636 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ POLB P06746 1/20 0.39
▸ BCHE P06276 1/20 0.38
▸ ACHE P22303 1/20 0.38
▸ BACE1 P56817 1/20 0.38
▸ HDAC8 Q9BY41 1/20 0.38
▸ GRIN2B Q13224 1/20 0.38
▸ TAAR1 Q96RJ0 1/20 0.38
▸ DPP8 Q6V1X1 2/20 0.37
▸ DPP9 Q86TI2 2/20 0.37
▸ DPP7 Q9UHL4 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5778665 0.83 UCHL1 (0.49) DRD2ABHD6
SCHEMBL18584701 0.80 ABHD6 (0.43) ALDH1A1MAPTHDAC8TAAR1KDM4E
SCHEMBL5774994 0.79 KDM4E (0.41) ALDH1A1TDP1TAAR1KDM4EKMT2A
SCHEMBL28901639 0.79 ABHD6 (0.41) MAPTTAAR1KDM4EMEN1KMT2A
SCHEMBL16268894 0.79 S1PR5 (0.40) ALDH1A1MAPTHDAC8TAAR1DPP8
SCHEMBL28245902 0.76 S1PR5 (0.51) MAPTTDP1POLBHDAC8TAAR1
SCHEMBL5777006 0.76 SMN1; SMN2 (0.44) ALDH1A1HDAC8TAAR1KDM4EMEN1
SCHEMBL6287145 0.76 KDM4E (0.40) MAPTPOLBTAAR1KDM4EMEN1
SCHEMBL22319819 0.75 S1PR5 (0.47) ALDH1A1MAPTTAAR1KDM4EMEN1
SCHEMBL5776465 0.75 CYP2A13 (0.44) ALDH1A1MAPTHDAC8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936619-B2 Cardiovascular disorders; antilipemic agents; sexual disorders PFIZER, INC. (US) 2005-08-30 — — US disclosed
US-20040029859-A1 Compounds useful in therapy PFIZER INC. 2004-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029859-A1 Compounds useful in therapy ADRA1D, HSD3B1, PTGER1 ALDH1A1 1113/4885MAPT 4800/4885TDP1 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback